A supplemental application for Opdivo (nivolumab) received FDA approval on August 19, 2021. This approval, designated BLA 125554 S-97, specifically pertains to the drug's efficacy, as confirmed by the U.S. Food and Drug Administration.
Background
Nivolumab, marketed under the brand name Opdivo, is a biologic product developed by Bristol Myers Squibb. As a previously approved therapeutic agent, supplemental approvals typically indicate an expansion or modification of its established uses. This particular supplemental approval focuses on new efficacy data, suggesting an update to the drug's approved indications or patient population based on demonstrated clinical benefit.
What this means
The supplemental FDA approval for Opdivo (nivolumab), based on new efficacy data, signifies a regulatory endorsement of additional clinical benefit for this established medication. While the specific details regarding the expanded indication, patient population, or updated dosing regimen are not detailed in the provided source, such approvals are crucial for broadening treatment options and optimizing patient care. This type of approval often results from new clinical trial data demonstrating effectiveness in a previously unapproved setting or a superior profile in an existing one. Clinicians and healthcare providers should consult the most current prescribing information for Opdivo to understand the full scope of this updated approval, including any new indications, contraindications, warnings, or precautions, to ensure appropriate patient selection and management.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-97, an efficacy supplement, was documented on August 19, 2021, on accessdata.fda.gov. The sponsor of this application is Bristol Myers Squibb.